NellOne Therapeutics Inc. believes it can help patients restore muscle mass and function thanks to a gene called Nell-1. If early studies bear out, the company’s research could yield protein therapeutics capable of regenerating muscle around joint replacements and even in hearts damaged by heart attacks. An in vitro study of heart muscle cells showed the protein could protect those cells and prevent them from dying in the very kind of low-oxygen situation that typifi es the conditions that heart muscle cells encounter during a heart attack. NellOne has chosen to develop its technology as a wound-healing therapy initially, because that research is farthest along and the path to market is shorter than for a cardiovascular indication.
10702 Murdock Road
Knoxville, TN 37932
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.
In first confirmatory randomized controlled trial of any CAR-T therapy in solid tumors, CARsgen’s Claudin 18.2-targeting satri-cel reduced risk of death or disease progression by 63% in Chinese patients with gastric/gastroesophageal junction cancer.
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
